Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021–February 2022

Sara S. Kim1 | Jessie R. Chung1 | H. Keipp Talbot2 | Carlos G. Grijalva2 | Karen J. Wernli3 | Erika Kiniry3 | Emily T. Martin4 | Arnold S. Monto4 | Edward A. Belongia5 | Huong Q. McLean5 | Manjusha Gaglani6,7 | Mufaddal Mamawala6 | Mary Patricia Nowalk9 | Krissy Moehling Geffel8 | Sara Y. Tartof9 | Ana Florea9 | Justin S. Lee1 | Mark W. Tenforde1 | Manish M. Patel1 | Brendan Flannery1 | Strain Surveillance and Emerging Variants Team1

1Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2Vanderbilt University Medical Center, Nashville, Tennessee, USA
3Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA
4University of Michigan School of Public Health, Ann Arbor, Michigan, USA
5Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA
6Baylor Scott and White Health, Temple, Texas, USA
7Texas A&M University College of Medicine, Temple, Texas, USA
8University of Pittsburgh Schools of Health Sciences, Pittsburgh, Pennsylvania, USA
9Kaiser Permanente Southern California, Pasadena, California, USA

Correspondence
Brendan Flannery, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Email: bif4@cdc.gov

Funding information
This work was supported by the US Centers for Disease Control and Prevention through contracts 75D30121C11513,

Abstract

Background: We estimated SARS-CoV-2 Delta- and Omicron-specific effectiveness of two and three mRNA COVID-19 vaccine doses in adults against symptomatic illness in US outpatient settings.

Methods: Between October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible participants who had fever, cough, or loss of taste or smell and sought outpatient medical care or clinical SARS-CoV-2 testing within 10 days of illness onset. Using the test-negative design, we compared the odds of receiving two or three mRNA COVID-19 vaccine doses among SARS-CoV-2 cases versus controls using logistic regression. Regression models were adjusted for study site, age, onset week, and prior SARS-CoV-2 infection. Vaccine effectiveness (VE) was calculated as \( \frac{1}{\text{adjusted odds ratio}} \times 100\% \).

Results: Among 3847 participants included for analysis, 574 (32%) of 1775 tested positive for SARS-CoV-2 during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. When Delta predominated, VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA two-dose recipients and 96% (95% CI: 93% to 98%) for three-dose recipients. When Omicron predominated, VE was 21% (95% CI: 6% to 41%) among two-dose recipients and 62% (95% CI: 48% to 72%) among three-dose recipients.
Conclusions: In this adult population, three mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the United States. These findings support the recommendation for a third mRNA COVID-19 vaccine dose.

KEYWORDS
COVID-19, outpatient, vaccine effectiveness

1 | BACKGROUND

On November 29, 2021, the Centers for Disease Control and Prevention (CDC) recommended that all adults aged ≥18 years receive a third mRNA COVID-19 vaccine booster dose at least 6 months after completing a two-dose primary series. The 6-month interval recommendation was shortened to at least 5 months on January 4, 2022, for the Pfizer-BioNTech vaccine and on January 7, 2022, for the Moderna vaccine. These recommendations were released during the emergence of the SARS-CoV-2 Omicron variant, which was first detected in the United States on December 1, 2021. Effectiveness of two mRNA vaccine doses against symptomatic illness or hospitalization due to infection with the Omicron variant has been lower compared with the Delta variant, with increased protection against both variants after receipt of a third dose. However, data comparing two- and three-dose vaccine effectiveness (VE) against symptomatic COVID-19 in outpatient settings during periods when the Delta and Omicron variants predominated are limited, especially among COVID-19 cases identified through active surveillance where all enrolled participants with COVID-19-like illness (CLI) are tested for SARS-CoV-2.

Studies with active enrollment such as the US Flu Vaccine Effectiveness Network (US Flu VE Network) provide access to specimens for research purposes including whole genome sequencing and access to data not available in medical records including risk factors for SARS-CoV-2 infection. To assess the impact of a third dose in the context of emerging variants with immune evasion and potential waning immunity, we estimated variant-specific effectiveness of two versus three mRNA vaccine doses against symptomatic illness in outpatient settings. Additionally, we utilized virus sequencing data to define periods when Delta and Omicron variants each predominated.

2 | METHODS

2.1 | Study design and population

This study was conducted within the US Flu VE Network, which consists of participating health systems in seven states: California, Michigan, Pennsylvania, Tennessee, Texas, Washington, and Wisconsin. Between October 1, 2021, and February 12, 2022, research staff screened patients seeking outpatient medical care or SARS-CoV-2 clinical testing with acute respiratory infection (ARI). Eligible participants reported onset of fever, cough, or loss of taste/smell with symptom duration of <10 days and had a clinical or research respiratory specimen collected for SARS-CoV-2 molecular testing within 10 days of illness onset. Research staff consented and enrolled eligible participants, who may have sought in-person medical care for ARI, completed a telehealth visit, or sought SARS-CoV-2 testing. Enrolled participants completed surveys with standardized questions across all research sites at enrollment including questions about demographics, symptoms experienced for current illness, COVID-19 vaccination history, prior SARS-CoV-2 infection, general health status, and high-risk SARS-CoV-2 exposures (healthcare worker with close patient contact; contact with another laboratory-confirmed SARS-CoV-2 case in the 14 days before illness onset; or household member with laboratory-confirmed SARS-CoV-2 or with symptoms consistent with COVID-19, i.e., cough, fever, chills, or loss of taste or smell, in the 14 days before illness onset). Participants were asked broadly whether they have any serious chronic medical condition such as heart disease, lung disease, diabetes, cancer, liver or kidney disease, immune suppression, or high blood pressure. Information about individual conditions, including severity, was not available. This activity was reviewed and approved by the CDC and each US Flu VE Network site’s Institutional Review Board.

2.2 | SARS-CoV-2 status

Participants were tested for SARS-CoV-2 by reverse-transcription polymerase chain reaction tests using respiratory specimens collected for clinical or research purposes. We classified participants with a positive SARS-CoV-2 result as cases. Participants who had discordant clinical and research results were categorized as a case if at least one of the results was positive. We classified participants with only negative SARS-CoV-2 results as controls.

In addition, SARS-CoV-2 virus variants from a subset of SARS-CoV-2 positive participants with onset dates between November 9, 2021, and January 9, 2022, were identified by whole genome sequencing. Research-collected SARS-CoV-2 positive respiratory specimens with cycle threshold values <30 and stored in appropriate transport medium were prepared for sequencing using the xGen SARS-CoV-2 library preparation kit (Integrated DNA Technologies, Inc., Coralville, IA). Libraries were sequenced on a NovaSeq
2.3 | COVID-19 vaccination status

COVID-19 vaccination status was verified using electronic medical records, immunization information systems, and vaccination record cards. Participants considered vaccinated with two doses were those who received two mRNA vaccine doses ≥14 days before illness onset (two-dose). To be considered for the two-dose analyses, participants must have received doses ≥16 days apart for Pfizer-BioNTech vaccines and ≥23 days apart for Moderna vaccines. Participants considered vaccinated with three doses were those who received three mRNA vaccine doses, where the third dose was given ≥7 days before illness onset (three-dose). Participants who received a third dose before the recommended ≥150 days after the second dose were also considered three-dose recipients but excluded from sensitivity analyses. Three-dose recipients included both immunocompromised participants who received a third dose as a primary series and otherwise healthy participants who received a third dose as a booster. Those who did not report vaccine receipt and had no documentation of an mRNA COVID-19 vaccination before illness onset were defined as unvaccinated. We excluded participants who self-reported COVID-19 vaccination but were missing verified documentation of doses received.

2.4 | Statistical analyses

We limited analyses to adults aged ≥18 years. Using the test-negative design, we compared the odds of two- or three-dose mRNA COVID-19 vaccination among COVID-19 cases versus test-negative controls using logistic regression. VE was calculated as (1–adjusted odds ratio) × 100%. Regression models were adjusted for variables identified a priori including study site, age, and illness onset week. Sex, race and ethnicity, illness onset to specimen collection interval, self-reported high-risk exposure, self-reported chronic medical condition, and self-reported prior SARS-CoV-2 infection were evaluated as model covariates using a change-in-estimate (≥5% change in odds ratio) forward stepwise approach. In addition to covariates included a priori, prior SARS-CoV-2 infection was included in the final regression model because its inclusion changed the OR by 8%. All other potential confounders examined changed the OR by <1%.

We evaluated VE by variant, either sequence-confirmed variant or using time periods of predominant Delta (illness onset of October 1–December 9, 2021) versus Omicron circulation (illness onset of December 20, 2021–February 12, 2022) when variant was not confirmed by sequencing. These periods were selected based on the SARS-CoV-2 sequencing results on a subset of cases in the US Flu VE Network. Due to co-circulation of the Delta and Omicron variants between December 10 and 19, 2021, we excluded participants without sequenced viruses with onset dates during this period for variant-specific estimates. We also assessed potential waning immunity among two-dose recipients by comparing VE of those who received their second dose 14–149 days versus ≥150 days prior to illness onset during each variant predominant period.

We conducted several subgroup analyses where three-dose VE was stratified by self-reported high-risk exposure status, self-reported chronic medical condition, self-reported prior SARS-CoV-2 infection, days between illness onset and specimen collection date, and self-reported presence of fever with cough or shortness of breath during the Delta and Omicron predominant periods. Analyses by illness onset to specimen collection interval were performed to identify bias resulting from potential false negative SARS-CoV-2 test results among participants who presented for care or testing later than those presenting 0–2 days after illness onset. Analyses by symptoms were performed to evaluate VE among persons with potentially more severe illness compared to those without fever paired with cough or shortness of breath, indicating more mild illness.

3 | RESULTS

3.1 | Study population

Between October 2021 and February 2022, US Flu VE Network sites enrolled 4448 eligible outpatients aged ≥18 years, among whom 601 were excluded due to receiving a non-mRNA vaccine (n = 216), self-reporting vaccination history with no documentation available (n = 145), receiving one mRNA COVID-19 vaccine dose (n = 121), missing vaccine product information (n = 55), missing SARS-CoV-2 testing information (n = 34), or having an indeterminate vaccination status (n = 30). Among 3847 included for analysis, 575 (32%) of 1775 participants tested SARS-CoV-2 positive during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. There were 278 participants whose illness onset dates fell between the defined Delta and Omicron predominance periods. SARS-CoV-2 positivity reached over 50% during the third week of December and peaked at 64% during the second week of January (Figure 1).

Over the entire study period, participants who self-reported a high-risk exposure or reported fever were more likely to test positive (Table 1). Additionally, participants who were aged ≥65 years, identified as White non-Hispanic or other race non-Hispanic compared with Black non-Hispanic or Hispanic, self-reported a chronic medical condition, and did not self-report a fever were more likely to receive a third vaccine dose (Table 2). Among two-dose recipients, the median interval between receipt of a second dose and illness onset date was 225 days (range 14–386); 13% and 87% had received a second mRNA vaccine dose 14–149 days or ≥150 days prior to illness onset, respectively (data not shown). The median interval between third dose receipt and illness onset was 53 days (range: 7–230) (data not shown).
3.2 Study periods by variant predominance

Sequencing results from 272 out of 873 SARS-CoV-2-positive US Flu VE Network participants with onset dates between November 9, 2021, and January 9, 2022, demonstrated distinct periods of Delta versus Omicron circulation with co-circulation of both variants during December 10–19, 2021 (Figure 2). Overall, 45% of sequenced specimens were Delta. The first Omicron variant in the network was detected on December 10, 2021, and it became the consistently predominant variant (>50% of sequenced viruses) by December 15, 2021, with few viruses in early January 2022 still being identified as Delta.

3.3 Vaccine effectiveness

During the Delta period, adjusted VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA two-dose recipients and 96% (95% CI: 93% to 98%) for three-dose recipients (Table 3). During the Omicron period, adjusted VE was 21% (95% CI: −6% to 41%) among two-dose recipients and 62% (95% CI: 48% to 72%) among three-dose recipients. During the Delta period, VE among participants who received their second dose 14–149 days before illness onset was 89% (95% CI: 78% to 94%) compared with 58% (95% CI: 44% to 68%) among those who received their second dose ≥150 days before illness onset (Table 3). During the Omicron period, VE among those who received their second dose 14–149 days before illness onset was 45% (14% to 66%) and among those who received their second dose ≥150 days before illness onset was 11% (−21% to 35%). Excluding three-dose recipients who received the third dose <150 days after the second dose (n = 35) did not change three-dose VE estimates (data not shown).

3.4 Vaccine effectiveness by subgroup

Self-reported high-risk exposure status, self-reported presence of a chronic medical condition, self-reported prior laboratory-confirmed SARS-CoV-2 infection, longer interval from illness onset to respiratory specimen collection, and self-reported presence of fever with cough or shortness of breath did not change three-dose VE during the Delta variant predominant period (Table 4). However, during the period when the Omicron variant predominated, three-dose VE point estimates tended to be lower but with overlapping confidence intervals among those who had a high-risk exposure, a chronic medical condition, a prior SARS-CoV-2 infection, or CLI that included fever. During the Delta period, 4% of cases and 14% of controls had prior infection compared with the Omicron period when 15% of cases and 20% of controls had prior infection.

4 DISCUSSION

This investigation adds to early evidence of effectiveness of a third mRNA vaccine dose against laboratory-confirmed SARS-CoV-2 infection among adults seeking outpatient care and clinical testing for CLI symptoms during the pandemic wave predominated by the Omicron variant. However, three-dose effectiveness among adults was lower during the Omicron predominant period than during the pandemic wave associated with the Delta variant. Similar to analyses of large electronic medical record databases or data from SARS-CoV-2 testing sites, three-dose VE in this analysis was higher against Delta than against Omicron-related illness.

Findings from the US Flu VE Network are also consistent with higher estimates of two-dose VE when the second dose was given less than 5 months before current illness onset compared with at least
|                              | Negative SARS-CoV-2 Participants with CLI | Positive SARS-CoV-2 Participants with CLI | P value\(^a\) |
|------------------------------|------------------------------------------|------------------------------------------|---------------|
| Total                        | 2208 100                                 | 1639 100                                 |               |
| Age group, y                 |                                          |                                          | 0.06          |
| 18–49                        | 1347 61                                  | 1027 63                                  |               |
| 50–64                        | 544 25                                   | 419 26                                   |               |
| ≥65                          | 317 14                                   | 193 12                                   |               |
| Site                         |                                          |                                          | <0.01         |
| California                   | 322 15                                   | 164 10                                   |               |
| Michigan                     | 166 8                                    | 188 11                                   |               |
| Pennsylvania                 | 311 14                                   | 320 20                                   |               |
| Tennessee                    | 269 12                                   | 186 11                                   |               |
| Texas                        | 262 12                                   | 159 10                                   |               |
| Washington                   | 296 13                                   | 110 7                                    |               |
| Wisconsin                    | 582 26                                   | 512 31                                   |               |
| Sex                          |                                          |                                          | <0.01         |
| Female                       | 1485 67                                  | 1017 62                                  |               |
| Male                         | 720 33                                   | 618 38                                   |               |
| Race/ethnicity               |                                          |                                          | <0.01         |
| Black, non-Hispanic          | 87 4                                     | 119 7                                    |               |
| Hispanic                     | 221 10                                   | 134 8                                    |               |
| Other, non-Hispanic          | 198 9                                    | 128 8                                    |               |
| White, non-Hispanic          | 1676 77                                  | 1218 76                                  |               |
| Self-reported chronic medical condition | | | 0.77 |
| No                           | 1514 70                                  | 1138 70                                  |               |
| Yes                          | 652 30                                   | 480 30                                   |               |
| High-risk exposure           |                                          |                                          | <0.01         |
| No                           | 1273 58                                  | 706 43                                   |               |
| Yes                          | 935 42                                   | 933 57                                   |               |
| Self-reported prior infection |                                          |                                          | <0.01         |
| No                           | 1841 84                                  | 1450 89                                  |               |
| Yes (6 missing)              | 350 16                                   | 179 11                                   |               |
| <3 months ago                | 194 56                                   | 110 63                                   | 0.12          |
| ≥3 months ago                | 154 44                                   | 65 37                                    |               |
| Product among vaccinated (2 and 3 doses) | | | |
| Moderna                      | 670 36                                   | 368 31                                   |               |
| Pfizer-BioNTech              | 1165 62                                  | 784 67                                   |               |
| Combination                  | 42 2                                     | 20 2                                     |               |
| Fever                        |                                          |                                          | <0.01         |
| No                           | 1233 56                                  | 649 40                                   |               |
| Yes                          | 950 44                                   | 968 60                                   |               |

Abbreviation: CLI, COVID-19-like illness.

\(^a\)P value for chi-square statistic.

\(^b\)Seven participants missing data on sex.

\(^c\)Sixty-six participants missing data on race and/or ethnicity.

\(^d\)Sixty-three participants missing data on chronic medical condition.

\(^e\)Twenty-seven participants missing data on self-reported prior SARS-CoV-2 infection.

\(^f\)Forty-seven participants missing data on presence of fever.
| Characteristics of symptomatic adults seeking outpatient medical care or SARS-CoV-2 clinical testing by mRNA COVID-19 verified vaccination status, US Flu VE Network, October 2021–February 2022 |
|---------------------------------------------------------------|
| **Unvaccinated**                                             |
| N | Row % | N | Row % | N | Row % | N | Row % | P value |
| Total | 798 | 21 | 256 | 7 | 1681 | 44 | 1112 | 29 |
| **Age group, y**                                             |
| <0.01 |
| 18–49 | 566 | 24 | 185 | 8 | 1099 | 46 | 524 | 22 |
| 50–64 | 181 | 19 | 63 | 7 | 399 | 41 | 320 | 33 |
| ≥65 | 51 | 10 | 8 | 2 | 183 | 36 | 268 | 53 |
| **Site**                                                     |
| <0.01 |
| California | 15 | 3 | 24 | 5 | 268 | 55 | 179 | 37 |
| Michigan | 50 | 14 | 15 | 4 | 183 | 52 | 106 | 30 |
| Pennsylvania | 208 | 33 | 29 | 5 | 292 | 46 | 102 | 16 |
| Tennessee | 56 | 12 | 44 | 10 | 194 | 43 | 161 | 35 |
| Texas | 130 | 31 | 49 | 12 | 179 | 43 | 63 | 15 |
| Washington | 12 | 3 | 23 | 6 | 210 | 52 | 161 | 40 |
| Wisconsin | 327 | 30 | 72 | 7 | 355 | 32 | 340 | 31 |
| **Sex**                                                      |
| 0.09 |
| Female | 496 | 20 | 168 | 7 | 1086 | 43 | 752 | 30 |
| Male | 302 | 23 | 88 | 7 | 589 | 44 | 359 | 27 |
| **Race/ethnicity**                                          |
| <0.01 |
| Black, non-Hispanic | 61 | 30 | 27 | 13 | 76 | 37 | 42 | 20 |
| Hispanic | 45 | 13 | 29 | 8 | 199 | 56 | 82 | 23 |
| Other, non-Hispanic | 32 | 10 | 16 | 5 | 170 | 52 | 108 | 33 |
| White, non-Hispanic | 646 | 22 | 180 | 6 | 1207 | 42 | 861 | 30 |
| **Self-reported chronic medical condition**                 |
| <0.01 |
| No | 584 | 22 | 193 | 7 | 1190 | 45 | 685 | 26 |
| Yes | 205 | 18 | 61 | 5 | 461 | 41 | 405 | 36 |
| **High-risk exposure**                                      |
| <0.01 |
| No | 406 | 21 | 134 | 7 | 916 | 46 | 523 | 26 |
| Yes | 392 | 21 | 122 | 7 | 765 | 41 | 589 | 32 |
| **Self-reported prior infection**                           |
| <0.01 |
| No | 626 | 19 | 198 | 6 | 1466 | 45 | 1001 | 30 |
| Yes (6 missing) | 169 | 32 | 55 | 10 | 200 | 38 | 105 | 20 |
| <3 months ago | 123 | 40 | 25 | 8 | 96 | 32 | 60 | 20 |
| ≥3 months ago | 45 | 21 | 29 | 13 | 101 | 46 | 44 | 20 |
| **Product among vaccinated (2 and 3 doses)**                |
| Moderna | 64 | 6 | 636 | 61 | 338 | 33 |
| Pfizer-BioNTech | 190 | 10 | 1045 | 54 | 714 | 37 |
| Combination | 2 | 3 | 0 | 0 | 60 | 97 |
| **Fever**                                                    |
| <0.01 |
| No | 325 | 17 | 120 | 6 | 795 | 42 | 642 | 34 |
| Yes | 468 | 24 | 135 | 7 | 862 | 45 | 453 | 24 |

*P value for chi-square statistic.
Seven participants missing data on sex.
Sixty-six participants missing data on race and/or ethnicity.
Sixty-three participants missing data on chronic medical condition.
Twenty-seven participants missing data on self-reported prior SARS-CoV-2 infection.
Forty-seven participants missing data on presence of fever.
5 months or more before illness onset.\textsuperscript{3,5} Waning effectiveness against SARS-CoV-2 Delta variant virus infection or associated outpatient illness was also observed 5 to 6 months after receipt of the second mRNA vaccine dose in other countries using multiple study designs.\textsuperscript{15–19} However, among US Flu VE Network participants, two-dose mRNA VE point estimate against outpatient illness associated with the Delta variant among those who received their second dose at least 5 months or more before illness onset remained higher than two-dose VE against Omicron among those who received their second dose <5 months before illness onset, with overlapping 95% confidence intervals. These results suggest that updates to COVID-19 vaccine formulations or additional booster doses may be needed to improve protection against future SARS-CoV-2 variant viruses.

Active enrollment of study participants in the US Flu VE Network provided additional information to evaluate differences in three-dose mRNA VE according to participants’ symptoms, reported history of past laboratory-confirmed SARS-CoV-2 infection, high-risk exposure, and presence of underlying medical conditions. First, among generally healthy outpatients with symptomatic illness enrolled in the US Flu VE Network, three-dose VE point estimates during the Omicron period tended to be lower among participants reporting underlying inflammation.

\textbf{TABLE 3} Two- and three-dose vaccine effectiveness during SARS-CoV-2 Delta variant or Omicron variant associated symptomatic COVID-19 illness among adults seeking outpatient medical care or SARS-CoV-2 clinical testing, US Flu VE Network, October 2021–February 2022

|                | SARS-CoV-2 positive | SARS-CoV-2 negative | Unadjusted VE | Adjusted\textsuperscript{*} VE |
|----------------|---------------------|---------------------|---------------|------------------------------|
|                | Vaccinated/Total (%)| Vaccinated/Total (%)| VE (95% CI)   | VE (95% CI)                  |
| Overall        |                     |                     |               |                             |
| 2-dose         | 822/1289 (64)       | 1115/1446 (77)      | 48 (38 to 56) | 48 (37 to 57)               |
| 3-dose         | 350/817 (43)        | 762/1093 (70)       | 67 (61 to 73) | 78 (72 to 83)               |
| Delta\textsuperscript{b} |                     |                     |               |                             |
| 2-dose         | 327/552 (59)        | 763/942 (81)        | 66 (57 to 73) | 63 (51 to 72)               |
| 14–149 days    | 14/239 (6)          | 106/285 (37)        | 89 (81 to 94) | 89 (78 to 94)               |
| ≥150 days      | 313/538 (58)        | 657/836 (79)        | 62 (52 to 70) | 58 (44 to 68)               |
| 3-dose         | 22/247 (9)          | 259/438 (59)        | 93 (89 to 96) | 96 (93 to 98)               |
| Omicron\textsuperscript{b} |                     |                     |               |                             |
| 2-dose         | 464/684 (68)        | 257/380 (68)        | 0 (−32 to 23) | 21 (−6 to 41)               |
| 14–149 days    | 69/289 (24)         | 53/176 (30)         | 27 (−11 to 52) | 45 (14 to 66)               |
| ≥150 days      | 395/615 (64)        | 204/327 (62)        | −8 (−43 to 18) | 11 (−21 to 35)             |
| 3-dose         | 322/542 (59)        | 408/531 (77)        | 56 (43 to 66) | 62 (48 to 72)               |

\textsuperscript{*}Logistic regression model adjusted for age, site, illness onset week, and prior infection status.

\textsuperscript{b}Totals in variant-specific periods may not add up to overall total as a transition period was included in the overall estimates but removed in the variant-specific periods.
Presence of underlying medical conditions, especially immunosuppressive conditions, have been associated with decreased mRNA VE against severe outcomes including COVID-19 related hospitalizations. Second, participants who reported a high-risk exposure in the 14 days before illness onset demonstrated lower three-dose VE during the Omicron predominant period compared with overall VE during this time. These results are consistent with previous studies, including an analysis of data from the US Flu VE Network during the Delta-predominant period. Third, the proportion of participants reporting previous laboratory confirmed SARS-CoV-2 infection was higher when the Omicron variant predominated than when the Delta variant predominated. However, we were unable to evaluate the impact of time since prior infection on VE due to small sample sizes. In contrast, prior studies have demonstrated increased protection among persons with prior SARS-CoV-2 infection history.

This investigation is subject to at least six limitations. First, small sample sizes limited our ability to evaluate VE by certain subgroups.
Differences between two- and three-dose mRNA VE by vaccine product, age group, and underlying medical conditions have been reported from studies including larger numbers of patients or medical encounters.\textsuperscript{2,5,11–15} Second, adolescents and children were not included in this analysis due to lower proportion of enrollment than in typical influenza seasons and lower percent vaccinated. Third, because of recent authorization of a booster dose for adults, waning of three-dose VE could not be assessed. Waning effectiveness of a booster dose against COVID-19 associated emergency department or urgent care visits has been reported elsewhere, though the study population may have differed to a certain extent from that of the US Flu VE Network.\textsuperscript{5} Fourth, with active enrollment, persons consenting to participate may differ from all patients in ways that may affect VE estimates, such as different healthcare-seeking behaviors among vaccinated and unvaccinated persons.\textsuperscript{10} Vaccinated SARS-CoV-2 positive patients may have been more likely than unvaccinated cases to participate in this study. Fifth, Delta versus Omicron misclassification among the subset of infections without sequencing results is possible. Finally, increased use of at-home testing may result in changes in healthcare seeking behavior and potential biases for VE studies, which requires further examination.

VE studies that rely on active enrollment of patients meeting clinical criteria for acute respiratory illness may contribute to ongoing monitoring of effectiveness of current and future COVID-19 vaccines.\textsuperscript{5} Studies in this outpatient setting also contribute to understanding vaccine protection against a spectrum of illness, adding effectiveness against symptomatic illness in outpatient settings to published inpatient, emergency department, and urgent care estimates for moderately severe and severe COVID-19. Systematic testing of outpatients presenting with CLI has the potential to identify SARS-CoV-2 positive cases and collect vaccination histories that may not be available from analyses of electronic medical records, especially as SARS-CoV-2 testing for persons with symptomatic illness becomes less frequent.\textsuperscript{22} As SARS-CoV-2 viruses evolve and COVID-19 continues to cause substantial respiratory illness, systematic testing for respiratory illnesses including COVID-19 and influenza will be important to evaluate effectiveness of COVID-19 vaccines and immunization schedules.

ACKNOWLEDGMENTS

Alexander Arroliga, Madhava Beearm, Kayan Dunnigan, Jason Ettinger, Ashley Graves, Eric Hoffman, Muralidhar Jatla, Amanda McKillop, Kempapura Murthy, Manohar Mutnal, Elisa Priest, Chandni Raiyani, Arundhati Rao, Lydia Requenez, Natalie Settele, Michael Smith, Keith Stone, Jennifer Thomas, Marcus Volz, Kimberly Walker, Martha Zayed, Baylor Scott & White Health, Temple, Texas and Texas A&M University College of Medicine, Temple, Texas; Ekow Annan, Peter Daley, Krista Kniss, Angiezel Merced-Morales, Influenza Division, CDC, Atlanta, GA; Elmer Ayala, Britta Amundsen, Michael Aragones, Raul Calderon, Vennis Hong, Gabriela Jimenez, Jeniffer Kim, Jen Ku, Bruno Lewin, Ashley McDaniel, Alexandria Reyes, Sally Shaw, Harp Takhar, Alicia Torres, Pasadena Medical Office Urgent Care Staff, Kaiser Permanente Southern California, Pasadena, California; Rachael Burganowski, Erika Kiniry, Kathryn A. Moser, Matt Nguyen, Suzie Park, Stacie Wellwood, Brianna Wickersham, Kaiser Permanente Washington Health Research Institute, Seattle, Washington; Juan Alvarado-Batres, Saydee Benz, Hannah Berger, Adam Bissonnette, Joshua Blake, Kristal Boese, Emily Botten, Jarod Boyer, Michaela Braun, Brianna Breu, Gina Burbay, Caleb Cravillon, Christian Delgadillo, Amber Donnerbauer, Tim Dziedzic, Joseph Eddy, Heather Edgren, Alex Ermeling, Kelsey Ewert, Connie Fechenbach, Rachel Fernandez, Wayne Frome, Sherri Guzinski, Linda Heeren, David Herda, Mitchell Hertel, Garrett Heuer, Erin Higdon, Lynn Ivacic, Lee Jepsen, Steve Kaiser, Julie Karl, Bailey Keffer, Jennifer King, Tamara Kronenwetter Koepel, Stephanie Kohl, Sarah Kohn, Diane Kohnhorst, Erik Kronholm, Thao Le, Alaura Lemieux, Carrie Marcis, Megan Maronde, Isaac McCready, Karen McGreevey, Jennifer Meece, Nidhi Mehta, Daniel Miesbauer, Vicki Moon, Jennifer Moran, Collin Nikolai, Brooke Olson, Jeremy Olstadt, Lisa Ott, Nan Pan, Cory Pike, DeeAnn Polacek, Martha Presson, Nicole Price, Christopher Rayburn, Chris Reardon, Miriah Rotar, Carla Rottschett, Jacklyn Salzwedel, Juan Saucedo, Kelly Scheffen, Charity Schug, Kristin Seyfert, Ram Shrestha, Alexander Slenczka, Elisha Stefanski, Melissa Strupp, Megan Tichenor, Lyndsay Watkins, Anna Zachow, Ben Zimmerman, Marshfield Clinic Research Institute, Marshfield, Wisconsin; Sarah Bauer, Kim Beney, Caroline K. Cheng, Nahla Faraj, Amy Getz, Michelle Grissom, Michelle Groesbeck, Samantha Harrison, Kristen Henson, Kim Jermanus, Emileigh Johnson, Anna Kanicildes, Armanda Kimberly, Lois E. Lamerato, Adam Lauring, Regina Lehmann-Wandell, E. J. McSpadden, Louis Nabor, Rachel Truscon, University of Michigan, Ann Arbor, Michigan and Henry Ford Health System, Detroit, Michigan; G.K. Balasubramani, Todd Bear, Jared Bobeck, Erin Bowser, Karen Clarke, Lloyd G. Clarke, Klancie Dauer, Chris Deluca, Blair Dierks, Linda Haynes, Robert Hickey, Monika Johnson, Andrea Jonsson, Nancy Luosang, Leah McKown, Alanna Peterson, Demetria Phaturos, Andrew Rectenwald, Theresa M. Sax, Miles Stiegler, Michael Susick, Joe Suyama, Louise Taylor, Sara Walters, Alexandra Weissman, John V. Williams, University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Marcia Blair, Juliana Carter, Jim Chappell, Emma Copen, Meredith Denney, Kellie Graes, Natasha Halasa, Chris Lindell, Zhouwen Liu, Stephanie Longmire, Rendie McHenry, Laura Short, His-Nien Tan, Denise Vargas, Jesse Wrenn, Dayna Wyatt, Yuwei Zhu, Vanderbilt University Medical Center, Nashville, Tennessee; Strain Surveillance and Emerging Variant Bioinformatics Working Group.

CONFLICT OF INTEREST

Ana Florea reports unrelated institutional grant support for research from Gilead, GlaxoSmithKline, Moderna, and Pfizer. Carlos G. Grijalva reports consulting fees from Merck, Pfizer, and Sanofi Pasteur, and institutional grant support from the Agency for Health Care Research and Quality, Campbell Alliance/Syneos Health, the Food and Drug Administration, and the National Institutes of Health. Emily T. Martin reports institutional grant support from Merck. Arnold S. Monto reports personal fees from Sanofi and non-financial support from
Seqirus. Mary Patricia Nowalk reports unrelated institutional grant support and personal fees from Merck Sharp & Dohme and institutional investigator-initiated grant support from Sanofi Pasteur. Sara Y. Tartof reports unrelated institutional grant support from Pfizer and GlaxoSmithKline. No other potential conflicts of interest were disclosed.

AUTHOR CONTRIBUTIONS
Sara Kim: Conceptualization; formal analysis; project administration. Jessie Chung: Conceptualization; data curation; methodology. Keipp Talbot: Data curation. Carlos Grijalva: Data curation. Karen Wernli: Data curation. Erika Kiniry: Data curation. Emily Martin: Data curation. Arnold Monto: Data curation. Huong Q. McLean: Data curation. Mufaddal Mamawala: Data curation. Mary Patricia Nowalk: Data curation. Krissy Moehling: Data curation. Sara Tartof: Data curation. Ana Florea: Data curation. Justin Lee: Data curation; methodology. Mark Tenforde: Conceptualization; methodology. Manish Patel: Conceptualization; supervision. Brendan Flannery: Conceptualization; methodology; supervision.

DISCLAIMERS
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Vaccination data from Pennsylvania were supplied by the Bureau of Health Statistics & Registries, Pennsylvania Department of Health, Harrisburg, Pennsylvania. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/irv.13029.

DATA AVAILABILITY STATEMENT
Data are available by request from the authors.

ORCID
Edward A. Belongia https://orcid.org/0000-0001-7478-0415
Mary Patricia Nowalk https://orcid.org/0000-0002-1702-2690
Brendan Flannery https://orcid.org/0000-0001-5041-308X

REFERENCES
1. Centers for Disease Control and Prevention. COVID-19 ACIP vaccine recommendations. Accessed March 14, 2022. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html
2. Centers for Disease Control and Prevention. Science Brief: Omicron (B.1.1.529) Variant, Accessed March 14, 2022. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html
3. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-145. doi:10.15585/mmwr.mm7104e3
4. Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118-124. doi:10.15585/mmwr.mm7104a2
5. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-263. doi:10.15585/mmwr.mm7107e2
6. Chung JR, Kim SS, Belongia EA, et al. Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February-September 2021. Influenza Other Respir Viruses. 2022;16(4):673-679. doi:10.1111/irv.12973
7. Nemt I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med. 2022;386(5):492-494. doi:10.1056/NEJMmc2119358
8. Chung JR, Kim SS, Jackson ML, et al. Clinical symptoms among ambulatory patients tested for SARS-CoV-2. Open Forum. 2021;8(1):ofaa576. doi:10.1093/ofid/ofaa576
9. O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus. Evolution. 2021 Sep 1;7(2):veab064. doi:10.1093/ve/veab064
10. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013 Apr 19;31(17):2165-2168. doi:10.1016/j.vaccine.2013.02.053
11. Accorsi ER, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and Delta variants. Jama. 2022 Feb 15;327(7):639-651. doi:10.1001/jama.2022.0470
12. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and Delta variants. Nat Med. 2022 Feb 21;1-1.
13. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N Engl J Med. 2022;386(19):1804-1816. doi:10.1056/NEJMoa2200797
14. Andrews N, Stowe J, Kirschbohm F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
15. Abu-Raddad LJ, Chemaitelly H, Bertolli L. National study group for COVID-19 vaccination. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. N Engl J Med. 2022;386(11):1091-1093. doi:10.1056/NEJMoa2119432
16. Chemaitelly H, Tang P, Hasan MR. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83. doi:10.1056/NEJMoa2114114
17. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85. doi:10.1056/NEJMoa2114228
18. Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022 Jan 27;386(4):340-350. doi:10.1056/NEJMoa2115481
19. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-944. doi:10.1016/S0140-6736(22)00152-0
20. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. *Lancet*. 2022;399(10327):814-823. doi:10.1016/S0140-6736(22)00089-7

21. Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. *Jama*. 2021;326(20):2043-2054. doi:10.1001/jama.2021.19499

22. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalisation and death in England. *Nat Med*. 2022;28(4):831-837. doi:10.1038/s41591-022-01699-1

23. Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September. *MMWR Morb Mortal Wkly Rep*. 2021;2021(44):1539-1544. doi:10.15585/mmwr.mm7044e1

24. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - Nine States, January-September 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70:1553-1559. doi:10.15585/mmwr.mm7044e3

25. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ*. 2022;376:e069761. doi:10.1136/bmj-2021-069761

26. Lewis NM, Naioti EA, Self WH, et al. Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March–August 2021. *J Infect Dis*. 2021;jiab619 doi:10.1093/infdis/jiab619

27. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. *The Lancet Regional Health - Americas*. 2022 Feb 14;100198.

28. Andrejko KL, Pry J, Myers JF, et al. Predictors of SARS-CoV-2 infection following high-risk exposure. *Clin Infect Dis*. 2021 Dec 21; ciab1040. doi:10.1093/cid/ciab1040

29. Fisher KA, Tenforde MW, Feldstein LR, et al. Community and close contact exposures associated with COVID-19 among symptomatic adults ≥18 years in 11 outpatient health care facilities - United States, July 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Sep 11;69(36):1258-1264. doi:10.15585/mmwr.mm6936a5

30. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. *N Engl J Med*. 2022;386(13):1288-1290. doi:10.1056/NEJMc2200133

31. León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis — California and New York, May–November 2021. *MMWR Morb Mortal Wkly Rep*. 2022 Jan 28;71(4):125-131. doi:10.15585/mmwr/mm7104e1

32. Flannery B, Meece JK, Williams JV, et al. Systematic testing for influenza and coronavirus disease 2019 among patients with respiratory illness. *Clin Infect Dis*. 2021;72(9):e426-e428. doi:10.1093/cid/ciaa1

How to cite this article: Kim SS, Chung JR, Talbot HK, et al. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021–February 2022. *Influenza Other Respi Viruses*. 2022;16(6):975-985. doi:10.1111/irv.13029